Protease-inhibitor boosting in the treatment-experienced patient

AIDS Reviews

Volumn 6, Issue 4, 2004, Pages 226-233

  Gallant, Joel E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Boosting; Pharmacokinetics; Protease inhibitor; Ritonavir

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHOLESTEROL; CYTOCHROME P450 3A4; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; CORONARY ARTERY DISEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXPERIENCE; FIRST PASS EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MEDICAL DECISION MAKING; NEPHROLITHIASIS; PATIENT CARE; PATIENT COMPLIANCE; REVIEW; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RITONAVIR;

EID: 13644249455     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998:338:853-60.
2. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 2002:288:222-35.
3. Van Praag R, Wit F, Jurriaans S, De Wolf F, Prins J, Lange J. Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 2002;16:719-25.
4. Hsu A, Granneman G, Bertz R. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-91.
5. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 2001;11:87-98.
6. Becker S. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs 2003:12:401-12.
7. Gerber J. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clin Infect Dis 2000;30 Suppl 2:123-9.
8. Cooper C, Van Heeswijk R, Gallicano K, Cameron D. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-92.
9. Cameron D, Japour A, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 1999;13:213-24.
10. O'Mara E, Mummaneni V, Bifano M, et al. Steady-state pharmacokinetic interaction study between BMS-232632 and ritonavir in healthy subjects. 8th CROI; February 2001; Chicago (IL) [abstract 740].
11. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldes M, O'Mara E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. 42nd ICAAC; September 2002; San Diego (CA). Abstract Book. Herndon, VA: ASM Press; 274 [abstract H-1716].
12. Bristol-Myers Squibb Company. BMS-232632: Atazanavir Briefing Document May, 2003. http://www.fda.gov/ohrms/dockets/ac/03/briefing/ 3950B1_01_bristolmyerssquibb-atazanavir.pdf. Accessed March 22, 2004.
13. Kurowski M, Kaeser B, Sawyer A, Popescu M, Mrozikiewicz A. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther 2002;72:123-32.
14. Bangsberg D, Hecht F, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66.
15. Sethi A, Celentano D, Gange S, Moore R, Gallant J. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003;37:1112-8.
16. Shulman N, Zolopa A, Havlir D, et al. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob Agents Chemother 2002;46:3907-16.
17. Marcelin A, Lamotte C, Delaugerre C, et al., and the Genophar Study Group. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003;47:594-600.
18. McCallister S, Kohlbrenner V, Squires K, et al. Characterization of the impact of genotype, phenotype, and inhibitory quotient on antiviral activity of tipranavir in highly treatment-experienced patients. Antivir Ther 2003;8 Suppl 1:15[abstract 12].
19. Kempf D, King M, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
20. Macmanus S, Yates P, White S, Richards N, Snowden W. GW433908 in ART-naive subjects: absence of resistance at 48 weeks with boosted regimen and APV-like resistance profile with unboosted regimen. 10th CROI; February 2003; Boston (MA) [abstract 598].
21. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidemic therapy with bezafibrate. J Infect 2001;42:181-8.
22. Penzak S, Chuck S. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23.
23. Buss N, Snell P, Bock J, Hsu A, Jorge K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br J Clin Pharmacol 2001; 52:255-64.
24. Arnaiz J, Mallolas J, Podzamczer D, et al., for the BEST Study Team. Continued indinavir vs. switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-40.
25. Gutiérrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003;33:594-600.
26. Gatell J, Lange J, Arnaiz J, Faetkenheuer G, Mallolas J, Clotet B. A randomized study comparing continued indinavir (800 mg tid) vs. switching to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load suppression with indinavir plus 2 nucleoside analogues. The Bid Efficacy and Safety Trial (BEST). XIII International AIDS Conference; 2000; Barcelona [abstract WeOrB484].
27. Benson C, Deeks S, Brun S, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185:599-607.
28. Feinberg J, Brun S, Xu Y, et al., for the M97-765 Study Group. Durable suppression of HIV+ RNA after 2 years of therapy with ABT-378/ritonavir (ABT-378/r) treatment in single protease inhibitor experienced patients. AIDS 2000;14 Suppl 4:46[abstract P101].
29. Danner S, Brun S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72 week safety/efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI experienced patients [abstract I-1925]. 41st ICAAC; December 2001; Chicago (IL) [abstract 344].
30. De Mendoza C, Martín-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002;3:304-9.
31. Katner H, Paar D, Nadler J, et al. Open-label study of a twice-daily indinavir 800 mg/ritonavir 200 mg regimen in HIV-infected adults failing a protease inhibitor regimen. J Acquir Immune Defic Syndr 2002;31:483-7.
32. Boyd M, Duncombe C, Ruxrungthram K, et al. Indinavir tid vs. indinavir/ritonavir bid in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow up. 9th CROI; February 2002; Seattle (WA) [poster 422-W].
33. Gerstoft J, Dragsted U, Cahn P, et al. Final analysis of a randomized trial to evaluate safety and efficacy of indinavir/ritonavir versus saquinavir/ritonavir in adult HIV-1 infection: the MaxCmin1 Trial. 42nd ICAAC; September 2002; San Diego (CA) [abstract H-172].
34. Plosker G, Scott L. Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 2003;63:1299-324.
35. Dragsted U, Gerstoft J, Pedersen C, et al., for the MaxCmin1 Trial Group. Randomized trial to evaluate indinavir/ritonavir vs. saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003;188:635-42.
36. Youle M, Gerstoft J, Fox Z, et al. The final week 48 analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) vs. saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: the MaxCmin2 Trial. 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment; July 2003; Paris [poster LB23].
37. Youle M, Gerstoft J, Fox Z, et al. The final week 48 analysis of a phase IV, randomised, open-label, multi-center trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) vs. saquinavir/ritonavir (1000/100 mg bid): The MaxCMin2 Trial. 9th European AIDS Conference (EACS); October 2003; Warsaw [abstract F11/3].
38. Walmsley S, Benetucci J, Brutus A, et al. Lipid profiles of patients enrolled in the MaxCmin 2 trial: a randomized, open-label multicenter comparative trial evaluating the safety and efficacy of lopinavir/ritonavir (400/100 mg twice daily) vs. saquinavir/ritonavir SQV/r (1000/100 mg twice daily). 11th CROI; February 2004, San Francisco (CA) [abstract 720].
39. Nadler J, Gathe J, Pollard R, et al., and the ESS40011 (STARR) Study Team. Twice-daily amprenavir 1200 mg vs. amprenavir 600 mg/ ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infect Dis 2003;3:10.
40. Schooley R, Haubrich R, Sension M, et al. Efficacy, safety and amprenavir (APV) pharmacokinetic (PK) responses of twice-daily APV and ritonavir (RTV) regimens in HIV-1 infected treatment-experienced adults for 48 weeks (ESS40006). 41st ICAAC; September 2001; Chicago (IL) [abstract 344].
41. Wood R, Trepo C, Livrozet J, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg bid or APV 1200 mg/RTV 200 mg qd given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART naive HIV-1 infected adults over 12 weeks (APV20001). 8th CROI; February 2001; Chicago (IL) [abstract 332].
42. Arasteh K, Wood R, Teofilo E, et al. Amprenavir (APV) 600 mg/ritonavir (RTV) 100 mg bid or APV 1.200 mg/RTV 200 mg qd given in combination with abacavir (ABC) and lamivudine (3TC) maintains efficacy in ART naive HIV-1 infected adults over 24-weeks (APV20001). 8th European Conference on Clinical Aspects and Treatment of HIV infection; October 2001; Athens [abstract P218].
43. DeJesus E, LaMarca A, Sension M, Beltrán C, Yeni P. The Context study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results). 10th CROI; February 2003; Boston (MA) [abstract 178].
44. Vertex Pharmaceuticals Incorporated. Vertex reports preliminary 48-week data from phase III study of 433908, an investigational HIV protease inhibitor. Press release. Press release dated July 24, 2003. Available at: www.vpharm.com/Pressreleases2003/pr072403.html. Accessed June 4, 2004.
45. DeJesus E, Grinsztejn B, Rodríguez C, et al. Efficacy and safety of atazanavir with ritonavir or saquinavir vs. lopinavir/ritonavir in patients who have experienced virologic failure on multiple HAART regimens: 48-week results from BMS A1424-045. 11th CROI; February 2004; San Francisco (CA) [abstract 547].
46. Clotet B, Lazzarin A, Grinsztejn B, Lichtenstein K, Sankoh S, Wilber R. Safety assessment of patients receiving atazanavir (9ATV) with ritonavir (RTV), ATV with saquinavir (SQV), or lopinavir (LPV)/RTV: 48-week results from BMS A1424-045. 13th International Symposium on HIV & Emerging Infectious Diseases; June 2004, Toulon, France [abstract PP 4.57].
47. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, for the AI424-007 Clinical Trial Group. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 2003;32:18-29.
48. Haas D, Zala C, Schrader S, et al. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. AIDS 2003;17:1339-49.
49. Murphy R, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003;17:2603-14.
50. Staszewski S, Dauer B, Von Hentig N, et al. The LOPSAQ study: 24-week analysis of the double protease inhibitor (PI) salvage regimen containing lopinavir (LPV/r) plus saquinavir (SQV) without any additional antiretroviral (ART) therapy. Antivir Ther 2003;8 Suppl 1 :342[abstract 583].
51. Raguin G, Chene G, Morand-Joubert L, and the Puzzle 1 Group. Salvage therapy with lopinavir/ritonavir (LPV/R), amprenavir (APV) ± an additional boost with ritonavir (RTV): 1-year results of puzzle 1-ANRS104 study. Antivir Ther 2003;8 Suppl 1:343[abstract 585].
52. Hellinger J, Cohen C, Morris A, et al. A pilot study of saquinavir-SGC (SQV) and lopinavir/ritonavir (LPV/R) twice daily in protease inhibitor (PI) naive HIV+ individuals: protease inhibitor concentrations and week 24 results. Antivir Ther 2003;8 Suppl 1:339[abstract 571].